investors & media
NASDAQ: (common stock)
Data Provided by Refinitiv. Minimum 15 minutes delayed.
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 24, 2020-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that the company will host a live webcast on December 7, 2020 at 7:00 p.m. ET to review clinical data presented at the 62 nd American Society of Hematology Annual Meeting and Exposition.Read more
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Nov. 10, 2020-- bluebird bio, Inc. (NASDAQ: BLUE) today announced that members of the management team will participate in the following upcoming investor conferences: Cowen 2020 IO Next Summit, Friday, November 13 , at 11:15 am ET Barclays Gene Editing & GeneRead more
Updated results from ongoing Phase 1/2 HGB-206 Group C Study of LentiGlobin™ for sickle cell disease gene therapy (bb1111) Long-term efficacy and safety results for betibeglogene autotemcel gene therapy in adult and pediatric patients with beta-thalassemia across genotypes (LTF-303, HGB-207,Read more